Joyce Cheng

发表

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer

K. Goldberg, R. Pazdur, L. Amiri-Kordestani, 2020, Clinical Cancer Research.

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer

R. Pazdur, Lijun Zhang, R. Sridhara, 2020, Clinical Cancer Research.

Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis.

R. Pazdur, J. Moslehi, L. Amiri-Kordestani, 2018 .

Inference Based on Small Randomized Oncology Clinical Trials: Is the Observed Treatment Effect True?

Joyce Cheng, 2017 .

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

K. Goldberg, R. Pazdur, L. Amiri-Kordestani, 2019, The Lancet. Oncology.

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2020, The oncologist.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Sarah E. Dorff, Amy McKee, R. Pazdur, 2016, Clinical Cancer Research.

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

R. Pazdur, L. Amiri-Kordestani, Tatiana M. Prowell, 2021, The Lancet. Oncology.

Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis

R. Pazdur, L. Amiri-Kordestani, Tatiana M. Prowell, 2021, SSRN Electronic Journal.

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Jiang Liu, R. Pazdur, R. Pragani, 2020, Clinical Cancer Research.

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Sarah E. Dorff, L. Fashoyin-Aje, K. Goldberg, 2020, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

L. Fashoyin-Aje, K. Goldberg, R. Pazdur, 2021, Clinical Cancer Research.

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

S. Khozin, P. Keegan, R. Pazdur, 2016, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies

K. Goldberg, R. Pazdur, Lijun Zhang, 2020, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

R. Pazdur, Todd R. Palmby, L. Amiri-Kordestani, 2018, Clinical Cancer Research.

Postoperative Complications in Chronic Lymphocytic Leukemia Patients Undergoing Mohs Surgery: Increased Risk of Bleeding-Related Complications From Ibrutinib.

T. Loh, K. Hirotsu, Joyce Cheng, 2022, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A U.S. Food and Drug Administration pooled analysis.

R. Pazdur, L. Amiri-Kordestani, Tatiana M. Prowell, 2018 .

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.

Jiang Liu, R. Pazdur, L. Amiri-Kordestani, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Amy McKee, R. Pazdur, Todd R. Palmby, 2016, Clinical Cancer Research.

Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

Seoho Lee, Joyce Cheng, N. Mangini, 2023, Breast Cancer Research and Treatment.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Amy McKee, R. Pazdur, R. Charlab, 2016, Clinical Cancer Research.

FDA Approval Summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma.

L. Fashoyin-Aje, R. Pazdur, Hong Zhao, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.

R. Pazdur, M. Theoret, N. Rahman, 2023, Journal of Clinical Oncology.